 In December 2012 raxibacumab was approved for the treatment of inhalational anthrax due to "Bacillus anthracis" in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences.Cambridge Antibody Technology discovered the antibody to Human Genome Sciences's target and, in 2012, HGS were purchased by GlaxoSmithKline (GSK).